Adalimumab Produits
(Adalimumab)
Catégories
antibodies-online.com est synonyme de produits de recherche de haute qualité. Cherchez, trouvez et commandez des outils avec des données de validation étendues, des images, des références. Notre service clientèle scientifique est toujours à votre disposition si vous avez des questions sur la sélection ou l'application de nos produits.
Adalimumab recommandé Anticorps
Produit
Reactivity
Application
Validations
N° du produit
Quantité
Fiche technique
Reactivity
Human
Application
ELISA
Validations
N° du produit
ABIN7514455
Quantité
40 μg
Fiche technique
Fiche technique
Reactivity
Human
Application
ELISA, BP
Validations
N° du produit
ABIN7514454
Quantité
40 μg
Fiche technique
Fiche technique
Reactivity
Human
Application
ELISA, BP
Validations
N° du produit
ABIN7514404
Quantité
40 μg
Fiche technique
Fiche technique
Adalimumab recommandé Kits ELISA
Produit
Reactivity
Analytical Method
Validations
N° du produit
Quantité
Fiche technique
Reactivity
Chemical, Human
Analytical Method
Quantitative Sandwich ELISA
Validations
- (1)
N° du produit
ABIN2862650
Quantité
96 tests
Fiche technique
Fiche technique
Reactivity
Human, Mouse, Rat
Analytical Method
Quantitative Sandwich ELISA
Validations
N° du produit
ABIN4886389
Quantité
96 tests
Fiche technique
Fiche technique
Dernières publications sur nos produits Adalimumab
: "Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease." dans: Journal of gastroenterology and hepatology, Vol. 33, Issue 3, pp. 631-637, (2018) (PubMed).: "IL26 modulates cytokine response and anti-TNF consumption in Crohn's disease patients with bacterial DNA." dans: Journal of molecular medicine (Berlin, Germany), Vol. 95, Issue 11, pp. 1227-1236, (2018) (PubMed).
: "Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease." dans: Alimentary pharmacology & therapeutics, Vol. 45, Issue 8, pp. 1135-1145, (2017) (PubMed).
: "Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis." dans: PLoS ONE, Vol. 11, Issue 12, pp. e0167757, (2017) (PubMed).
: "Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study." dans: Pediatric gastroenterology, hepatology & nutrition, Vol. 19, Issue 2, pp. 116-22, (2016) (PubMed).
: "Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation." dans: Scandinavian journal of gastroenterology, Vol. 51, Issue 2, pp. 196-202, (2016) (PubMed).
: "Adalimumab trough levels and response to biological treatment in patients with inflammatory bowel disease: a useful cutoff in clinical practice." dans: The American journal of gastroenterology, Vol. 110, Issue 3, pp. 472-3, (2015) (PubMed).
: "Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease." dans: Journal of gastroenterology, Vol. 50, Issue 7, pp. 758-68, (2015) (PubMed).
: "Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease." dans: Gut, Vol. 63, Issue 2, pp. 272-80, (2014) (PubMed).
: "Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children." dans: Inflammatory bowel diseases, Vol. 20, Issue 3, pp. 495-501, (2014) (PubMed).
Avez-vous cherché autre chose?
Vous êtes ici:
